Crossmark

Letter to the Editor Regarding “Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”

Crossref DOI link: https://doi.org/10.1007/s40123-026-01440-y

Published Online: 2026-07-11

Published Print: 2026-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Panos, Georgios D. https://orcid.org/0000-0001-8399-7456
License Information

Text and Data Mining valid from 2026-07-11

Version of Record valid from 2026-07-11
More Information

Article History

Received: 7 April 2026

Accepted: 9 June 2026

First Online: 11 July 2026

Declarations

Conflict of Interest: Georgios D. Panos declares travel grants and honoraria from Bayer, Roche and Thea.

Ethical Approval: Ethical approval was not required, as this letter does not report new studies involving human participants or animals.

Document is current

Any future updates will be listed below